NAS:ATNX (USA) Also trade in: Germany

Athenex Inc

$ 14 0.16 (1.16%)
Volume: 337,876 Avg Vol (1m): 382,444
Market Cap $: 1.08 Bil Enterprise Value $: 1.04 Bil
P/E (TTM): 0.00 P/B: 8.76
Earnings Power Value 0
Net Current Asset Value 0.56
Tangible Book 0.88
Projected FCF 0
Median P/S Value 16.12
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.50
Cash-To-Debt ranked higher than
50.09% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ATNX: 1.5
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.27, Med: 11.97, Max: 64.03
Current: 1.5
1.27
64.03
Equity-to-Asset 0.49
Equity-to-Asset ranked higher than
65.01% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ATNX: 0.49
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.32, Med: 0.65, Max: 0.79
Current: 0.49
0.32
0.79
Debt-to-Equity 0.45
Debt-to-Equity ranked higher than
92.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ATNX: 0.45
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.06, Max: 0.98
Current: 0.45
0.01
0.98
Debt-to-EBITDA -0.32
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ATNX: -0.32
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.39, Med: -0.23, Max: -0.02
Current: -0.32
-0.39
-0.02
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.68
DISTRESS
GREY
SAFE
Beneish M-Score -1.43
Not Manipulator
Manipulator

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -200.08
Operating Margin ranked lower than
50.25% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ATNX: -200.08
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -417.24, Med: -326.38, Max: -142.33
Current: -200.08
-417.24
-142.33
Net Margin % -189.86
Net Margin ranked lower than
52.40% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ATNX: -189.86
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -426.82, Med: -353.84, Max: -131.81
Current: -189.86
-426.82
-131.81
ROE % -105.59
ROE ranked lower than
71.79% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ATNX: -105.59
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -211.83, Med: -117.97, Max: -51.87
Current: -105.59
-211.83
-51.87
ROA % -67.89
ROA ranked lower than
72.05% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ATNX: -67.89
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -106.51, Med: -70.37, Max: -42.02
Current: -67.89
-106.51
-42.02
ROC (Joel Greenblatt) % -878.29
ROC (Joel Greenblatt) ranked lower than
58.98% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ATNX: -878.29
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1622.13, Med: -1116.27, Max: -750.87
Current: -878.29
-1622.13
-750.87
3-Year Total Revenue Growth Rate 85.60
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ATNX: 66.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate -35.40
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ATNX: -21.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A

» ATNX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ATNX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:MRTX SZSE:000518 SHSE:603896 NAS:RGNX HKSE:01681 SAU:2070 SZSE:300149 NAS:GERN NYSE:BHVN SZSE:002872 SZSE:300255 NAS:AMRN XPAR:GNFT XKRX:102940 SZSE:300204 NAS:NTLA XKRX:078160 HKSE:06826 SZSE:002022 SZSE:300147
Traded in other countries 2MT.Germany
Address 1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.

Ratios

Current vs industry vs history
PB Ratio 8.76
PB Ratio ranked lower than
71.93% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ATNX: 8.76
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.93, Med: 7.56, Max: 11.21
Current: 8.76
4.93
11.21
PS Ratio 12.08
PS Ratio ranked lower than
55.51% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ATNX: 12.08
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.88, Med: 13.94, Max: 44.92
Current: 12.08
7.88
44.92
EV-to-EBIT -6.86
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ATNX: -6.86
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -11.8, Med: -6.65, Max: -3.9
Current: -6.86
-11.8
-3.9
EV-to-EBITDA -7.01
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ATNX: -7.01
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -12.3, Med: -6.8, Max: -4
Current: -7.01
-12.3
-4
EV-to-Revenue 13.63
EV-to-Revenue ranked lower than
51.75% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ATNX: 13.63
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 7.4, Med: 13.2, Max: 37.5
Current: 13.63
7.4
37.5
Current Ratio 2.22
Current Ratio ranked lower than
56.24% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ATNX: 2.22
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.17, Med: 3.12, Max: 4.46
Current: 2.22
1.17
4.46
Quick Ratio 1.85
Quick Ratio ranked lower than
58.29% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ATNX: 1.85
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.98, Med: 2.73, Max: 3.86
Current: 1.85
0.98
3.86
Days Inventory 157.06
Days Inventory ranked lower than
53.22% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ATNX: 157.06
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 69.38, Med: 120.74, Max: 176.07
Current: 157.06
69.38
176.07
Days Sales Outstanding 98.08
Days Sales Outstanding ranked higher than
71.11% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ATNX: 98.08
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 49.32, Med: 67.15, Max: 100.31
Current: 98.08
49.32
100.31
Days Payable 133.89
Days Payable ranked higher than
75.19% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ATNX: 133.89
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 100.92, Med: 153.41, Max: 242.04
Current: 133.89
100.92
242.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -11.60
3-Year Share Buyback Rate ranked lower than
100.00% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ATNX: -11.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.91
Price-to-Tangible-Book ranked lower than
76.06% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ATNX: 15.91
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 8.82, Med: 13.21, Max: 21.2
Current: 15.91
8.82
21.2
Price-to-Median-PS-Value 0.87
Price-to-Median-PS-Value ranked higher than
68.88% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ATNX: 0.87
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.65, Med: 1.02, Max: 2.74
Current: 0.87
0.65
2.74
Earnings Yield (Joel Greenblatt) % -14.62
Earnings Yield (Greenblatt) ranked lower than
52.27% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ATNX: -14.62
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.8, Med: -15.05, Max: -8.4
Current: -14.62
-25.8
-8.4

More Statistics

Revenue (TTM) (Mil) $ 76.57
EPS (TTM) $ -2.22
Beta 0
Volatility % 42.2
52-Week Range $ 9.38 - 20.9
Shares Outstanding (Mil) 77.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N